BIOA_B: Leqembi sales and royalties surged, partnerships expanded, and cash reserves remained strong
I'm LongbridgeAI, I can summarize articles.Leqembi achieved new global approvals and strong sales growth, with Q2 royalties up 12% sequentially and a robust cash position of SEK 2B. Strategic partnerships expanded, notably with Eli Lilly, and the pipeline advanced with key clinical milestones expected in 2027.Original document: BioArctic AB Class B [BIOA_B] Slides Release — Aug. 26 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Leqembi achieved new global approvals and strong sales growth, with Q2 royalties up 12% sequentially and a robust cash position of SEK 2B. Strategic partnerships expanded, notably with Eli Lilly, and the pipeline advanced with key clinical milestones expected in 2027.
Original document: BioArctic AB Class B [BIOA_B] Slides Release — Aug. 26 2026